CMS FY 2027 Hospice Rule Introduces HOPE Assessment Waiver

The Centers for Medicare & Medicaid Services (CMS) continues to reshape hospice regulatory expectations through the Fiscal Year (FY) 2027 Hospice Wage Index and Payment Rate Update Proposed Rule. One of the most operationally significant updates within this rule is the introduction of a temporary waiver for the Hospice Outcomes and Patient Evaluation (HOPE) assessment timeliness requirements.

This development comes at a critical moment for hospice agencies across the United States, as providers are actively transitioning to new reporting frameworks while adapting to evolving compliance expectations. CMS has acknowledged these challenges and implemented a limited waiver designed to support providers during this transition.

However, while this waiver offers temporary relief, it also signals a broader regulatory direction that emphasizes accountability, data integrity, and long-term operational standardization.

This article provides a comprehensive breakdown of the HOPE assessment waiver, its implications, and how hospice agencies should strategically respond.

Understanding the HOPE Assessment Framework

The HOPE (Hospice Outcomes and Patient Evaluation) assessment is a relatively new standardized data collection instrument introduced by CMS. It is designed to:

• Improve patient outcome tracking

• Enhance care planning accuracy

• Strengthen quality reporting across hospice settings

• Align hospice documentation with broader CMS data initiatives

HOPE replaces or supplements prior assessment structures and introduces a more robust, data-driven approach to evaluating patient needs and outcomes.

Unlike previous documentation tools, HOPE requires:

• More detailed clinical inputs

• Timely submission of assessments

• Strong alignment between patient condition, interventions, and outcomes

This creates a higher level of operational complexity, particularly for agencies that have not yet fully optimized their documentation workflows.

The Role of iQIES in Hospice Reporting

Simultaneously, CMS has been transitioning providers to the iQIES (Internet Quality Improvement and Evaluation System) platform, which serves as the central hub for quality reporting and data submission.

The migration to iQIES represents a major technological shift, requiring agencies to:

• Learn a new system interface

• Adjust submission workflows

• Troubleshoot technical errors and rejections

• Ensure accurate data transmission

For many hospice providers, this dual transition—new assessment framework (HOPE) and new reporting system (iQIES)—has created operational strain.

CMS has explicitly recognized these challenges, which directly led to the implementation of the HOPE assessment waiver.

Key Details of the HOPE Assessment Waiver

The waiver introduced under the FY 2027 Proposed Rule includes the following provisions:

• Applies to HOPE assessments with target dates between October 1, 2025, and December 31, 2025

• All assessments within this timeframe will be considered timely, regardless of actual submission date

• Designed to accommodate:

  • System transition issues

  • Training gaps

  • Workflow disruptions

This waiver effectively removes timeliness-based penalties for HOPE assessments during the specified period.

Why CMS Issued the Waiver

CMS does not typically relax reporting requirements without clear justification. The decision to grant this waiver reflects several underlying realities:

1. Industry-Wide Implementation Challenges

Hospice agencies vary widely in size, resources, and technological capability. Many providers have experienced:

• Delays in staff training

• Confusion regarding HOPE requirements

• Difficulty integrating HOPE into existing EMR systems

2. Technical Barriers with iQIES

The rollout of iQIES has introduced:

• Submission errors

• Access issues

• Learning curve challenges

These issues have directly impacted providers’ ability to meet submission deadlines.

3. Risk of Widespread Noncompliance

Without intervention, CMS likely anticipated:

• High rates of late submissions

• Increased deficiencies during surveys

• Disruption in quality reporting data

The waiver serves as a preventative measure to stabilize the system during early adoption.

What the Waiver Does NOT Do

It is critical for providers to understand that this waiver is limited in scope.

The waiver does NOT:

• Eliminate the requirement to complete HOPE assessments

• Relax clinical documentation standards

• Remove quality reporting obligations

• Protect agencies from deficiencies related to inaccurate or incomplete data

In other words, only timeliness is waived—not compliance as a whole.

Survey and Audit Implications

From a regulatory standpoint, surveyors and auditors will continue to evaluate hospice agencies based on:

Clinical Accuracy

• Does the HOPE assessment reflect the patient’s actual condition?

• Are symptoms, diagnoses, and interventions appropriately documented?

Consistency

• Is there alignment between:

  • HOPE assessment

  • Plan of care

  • Clinical notes

  • IDG documentation

Completeness

• Are all required fields filled out correctly?

• Are assessments comprehensive and reflective of patient needs?

Operational Integrity

• Does the agency demonstrate a functional process for completing and submitting HOPE assessments?

Agencies that rely on the waiver as an excuse for poor documentation practices will remain vulnerable to deficiencies.

Operational Impact on Hospice Agencies

Short-Term Effects

The immediate benefit of the waiver includes:

• Reduced pressure on submission timelines

• Flexibility in workflow adjustments

• Ability to focus on training and system integration

This provides breathing room for agencies still stabilizing their processes.

Long-Term Effects

The long-term implications are more significant:

• CMS will likely enforce stricter compliance after the waiver period

• Agencies that fail to adapt now will face increased risk later

• Data collected during this period may still influence quality measures

This creates a clear expectation: use the waiver period strategically or face consequences later.

Strategic Recommendations from HealthBridge

At HealthBridge, we advise hospice agencies to approach this waiver as a controlled transition period, not a pause in compliance efforts.

1. Build a Standardized HOPE Workflow

Develop a clear internal process that includes:

• Defined responsibilities for each team member

• Timelines for assessment completion

• Quality checks before submission

Standardization reduces variability and improves compliance.

2. Conduct Internal Audits

Implement routine audits to evaluate:

• Accuracy of assessments

• Alignment with clinical documentation

• Timeliness of internal completion (even if submission is delayed)

This ensures readiness once enforcement resumes.

3. Invest in Staff Training

Your clinical team must fully understand:

• HOPE assessment requirements

• Documentation expectations

• Common errors and how to avoid them

Training should be ongoing, not one-time.

4. Optimize EMR Integration

Evaluate how your EMR system handles:

• HOPE data entry

• Data extraction and submission

• Error reporting

If inefficiencies exist, address them now.

5. Prepare for January 1, 2026

This is the most critical point.

By the end of 2025, your agency should be:

• Fully compliant with HOPE requirements

• Submitting assessments on time

• Operating without reliance on regulatory leniency

Common Risk Areas

Even with the waiver, agencies frequently encounter the following issues:

• Incomplete assessments

• Copy-paste documentation practices

• Misalignment between clinical notes and HOPE data

• Lack of oversight or audit processes

• Insufficient staff training

These issues often lead to deficiencies during surveys.

Regulatory Outlook: What This Signals

CMS’s decision to implement a waiver reflects a broader regulatory philosophy:

Transitional Flexibility + Long-Term Enforcement

CMS is willing to provide short-term accommodations, but expectations will ultimately increase.

We anticipate:

• Stricter enforcement post-2025

• Increased focus on data accuracy

• Greater integration of HOPE into quality metrics

This aligns with CMS’s broader movement toward data-driven healthcare regulation.

Competitive Advantage for Proactive Agencies

Hospice agencies that act early will benefit in several ways:

• Stronger survey outcomes

• Reduced risk of deficiencies

• Improved operational efficiency

• Better patient care documentation

In contrast, agencies that delay adaptation will face:

• Increased regulatory scrutiny

• Operational disruption

• Potential financial penalties

Conclusion

The HOPE assessment waiver introduced under the FY 2027 Hospice Proposed Rule is a necessary and strategic adjustment by CMS to support providers during a complex transition period.

However, this waiver is temporary and limited. It does not reduce the overall expectations for compliance, documentation accuracy, or quality reporting.

Hospice agencies must take decisive action now to:

• Strengthen workflows

• Train staff

• Optimize systems

• Prepare for full enforcement

The organizations that treat this period as an opportunity—not a delay—will emerge stronger, more compliant, and better positioned for future regulatory demands.

How HealthBridge Can Help

HealthBridge provides specialized consulting services for hospice agencies, including:

• HOPE assessment implementation and training

• iQIES workflow optimization

• Compliance audits and mock surveys

• Plan of Correction (POC) development

• Survey readiness preparation

Our team ensures your agency is not only compliant but operationally strong.

References

https://www.cms.gov
https://www.cms.gov/medicare/payment/prospective-payment-systems/hospice
https://www.cms.gov/medicare/quality/hospice/hospice-quality-reporting-program
https://iqies.cms.gov
https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-418